Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer
- Kuppen, Malou C. P.
- Westgeest, Hans M.
- van der Doelen, Maarten J.
- van den Eertwegh, Alphonsus J. M.
- Coenen, Jules L. L. M.
- Aben, Katja K. H.
- van den Bergh, Alphons C. M.
- Bergman, Andries M.
- van den Bosch, Joan
- Celik, Filiz
- Hendriks, Mathijs P.
- Lavalaye, Jules
- van der Meer, Saskia
- Polee, Marco B.
- Somford, Diederik M.
- van Oort, Inge M.
- Uyl-de Groot, Carin A.
- Gerritsen, Winald R.
DOIAbstract
Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p <0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018....
Add to ORKG